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ABSTRACT Dopamine (DA) deficiency has been impli-
cated in Lesch-Nyhan disease (LND), a genetic disorder that
is characterized by hyperuricemia, choreoathetosis, dystonia,
and compulsive self-injury. To establish that DA deficiency is
present in LND, the ligand WIN-35,428, which binds to DA
transporters, was used to estimate the density of DA-contain-
ing neurons in the caudate and putamen of six patients with
classic LND. Comparisons were made with 10 control subjects
and 3 patients with Rett syndrome. Three methods were used
to quantify the binding of the DA transporter so that its
density could be estimated by a single dynamic positron
emission tomography study. These approaches included the
caudate- or putamen-to-cerebellum ratio of ligand at 80-90
min postinjection, kinetic analysis of the binding potential
[Bmax/(Kd-Vd)] using the assumption of equal partition coef-
ficients in the striatum and the cerebellum, and graphical
analysis of the binding potential. Depending on the method of
analysis, a 50-63% reduction of the binding to DA transport-
ers in the caudate, and a 64-75% reduction in the putamen of
the LND patients was observed compared to the normal control
group. When LND patients were compared to Rett syndrome
patients, similar reductions were found in the caudate (53-61%)
and putamen (67-72%) in LND patients. Transporter binding in
Rett syndrome patients was not significantly different from the
normal controls. Finally, volumetric magnetic resonance imag-
ing studies detected a 30%o reduction in the caudate volume of
LND patients. To ensure that a reduction in the caudate volume
would not confound the results, a rigorous partial volume
correction ofthe caudate time activity curve was performed. This
correction resulted in an even greater decrease in the caudate-
cerebellar ratio in LND patients when contrasted to controls. To
our knowledge, these findings provide the first in vivo documen-
tation ofa dopaminergic reduction in LND and illustrate the role
ofpositron emission tomography imaging in investigating neuro-
developmental disorders.
Several neurodevelopmental disorders are thought to involve
the neuropathology of the basal ganglia. Among them, the best
known are Lesch-Nyhan disease (LND) and Rett syndrome. In
both of these conditions, there is evidence for the dysfunction
of the dopaminergic neurotransmission.
LND is an X-chromosome-linked disease with infantile
onset characterized by hyperuricemia, choreoathetosis, dysto-
nia, and compulsive self-injury (1). The underlying defect is a
near absence of hypoxanthine-guanine phosphoribosyl trans-
ferase (HPRT) (2), an enzyme that is normally present in the
brain in greater amounts than in other organs. Three lines of
evidence suggest that HPRT deficiency is linked to abnormal
dopamine (DA) function in LND: (i) an autopsy study of three
LND subjects demonstrated a marked reduction in the DA
content and in the activity of DA-synthesizing enzymes in the
caudate and putamen (3); (ii) when neonatal rats are depleted
of DA with the neurotoxin 6-hydroxydopamine, self-injurious
behavior (similar to that seen in LND) occurs when the rats are
challenged with 3,4-dihydroxyphenylalanine (L-dopa) as adults
(4, 5); and (iii) in an HPRT-deficient mutant mouse strain,
there is a reduction of striatal tyrosine hydroxylase and in the
number of striatal dopamine transporters measured with 3H-
N-[1-(2-benzo(,B)thiophenyl) cyclohexyl]piperidine (3H-
BTCP) (6). The pertinence of the loss of brain DA in LND has
been questioned due to the limited scope of the autopsy study
and the fact that the HPRT-deficient mouse study showed only
a modest reduction ofDA with no self-injury, or other clinical
symptoms of LND (6). Therefore the question of dopamine
reduction in vivo remains unresolved.
The availability of positron emission tomography (PET) li-
gands that bind to pre- or postsynaptic DA sites has made it
possible to study the DA system in vivo in patients affected with
disorders that involve the basal ganglia. For example, the DA
transporter probe ,3-carbomethoxy-3,3-4-fluorophenyl-tropane
(CFT; WIN-35,428) (7-11) has been used to detect the degen-
eration ofDA nerve terminals in adult humans (12,13). It has also
been used to measure the degeneration of nerve terminals in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated
primates and in idiopathic Parkinson disease (14-16). In addition,
WIN-35,428 is suitable for evaluating the integrity of DA-
containing neurons in neurodevelopmental disorders.
In the present investigation, the hypothesis- that HPRT
deficiency in LND is associated with impaired development of
dopaminergic projections to the striatum-was tested by de-
termining the number ofDA transporters in vivo by using PET
with the radiolabeled DA transporter ligand WIN-35,428. The
measurement of the presynaptic DA sites of WIN-35,428 using
PET provides a relevant assessment of the degree of dopami-
nergic deficiency in LND.
The binding of [11C] WIN-35,428 in LND patients was
compared to the binding in healthy volunteers and in patients
with Rett syndrome. Subjects with LND or Rett syndrome
were studied under anesthesia while the normal controls were
not sedated. Rett syndrome was chosen for comparison be-
cause of its stereotypical hand-to-mouth movement symptoms
that might be linked to the DA system, findings of reduced DA
Abbreviations: LND, Lesch-Nyhan disease; HPRT, hypoxanthine-
guanine phosphoribosyl transferase; PET, positron emission tomog-
raphy; DA, dopamine, L-dopa, 3,4-dihydroxyphenylalanine.
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metabolites in brain tissue, and observations of reduced mel-
anin content in the substantia nigra pars compacta (17, 18).
Patients with Rett syndrome served as a control group for the
potential effects of anesthesia and reduced caudate volume on
the DA transporter function (vide infra).
SUBJECTS, MATERIALS, AND METHODS
We studied 6 patients with classical LND (HPRT levels < 1%
of normal) (age range, 19-35 years; mean age, 23.7 ± 2.3
(SEM) years), 3 patients with Rett syndrome (age range, 18-23
years; mean age, 20.0 ± 1.5 years), and 10 age-matched normal
volunteers (age range, 19-46 years; mean age, 28.8 + 2.4
years) who were free of psychiatric or neurological disease.
None of the LND patients took neuroleptic drugs that bind to
DA nerve terminals; two used valium which was discontinued
3 weeks before the study, and one LND patient was taking
anticonvulsants (mysoline and phenobarbital). None of the
Rett syndrome patients took neuroleptics, but all were previ-
ously treated with anticonvulsant drugs. None of the normal
control group ever took psychotrophic drugs.
The PET studies of the LND and Rett syndrome patients
were conducted using light general anesthesia to prevent
involuntary movements. Studies in rodents demonstrated that
anesthesia does not affect the binding of ligands to the DA
transporter (19). The anesthesia procedure consisted of rectal
methohexital, inhalation of nitrous oxide, and administration
of pancuronium. Subjects were intubated and mechanically
ventilated (end tidal CO2 = 40 + 5 mmHg) by an anesthesi-
ologist (M.Y.). Heart rate and blood pressure did not vary
>10% from the baseline. The normal controls were not
sedated. The specific activity of [11C]WIN-35,428 (<10 ,ug
mass/injection) was greater than 1 ,uCi/pmol (i Ci = 37 GBq).
Fifty individual time frames were acquired by a GE 4096+
whole-body tomograph during a 90-min interval (20). HPLC
analysis of radiolabeled metabolites in the radial artery plasma
samples used the method of Wong et al. (20). To allow for
reproducible positioning in the PET scanner, an x-ray com-
puted tomography (CT) scan was performed. In five LND
patients, the eight normal control subjects, and the three Rett
syndrome patients, volumetric magnetic resonance imaging
(MRI) images were acquired with a spoiled grass sequence
(SPGR), (TE, 5.0 ms; TR, 35 ms; flip angle, 450; field of view
24 cm) yielding 124 contiguous slices 1.5 mm thick, and 256 x
192 image matrix. The images were then co-registered to the
PET scans using the program REGISTER (21).
The three methods of analysis used to estimate DA trans-
porter binding involved either (i) the caudate- or putamen-
to-cerebellum ratio measured during the last three frames of
PET imaging (-72-90 min postinjection) or (ii) the binding
potential, which is the ratio of the dopamine transporter
density (Bma,) to the affinity (Kd) and volume of distribution
of the tracer ligand in brain relative to water (Vd), in other
terms, Bm,,/(Kd-Vd). This binding potential was estimated by
linear or nonlinear regression. These methods have been
described previously. Briefly stated, the linear method is based
on the graphical approach of estimating rate constants (22, 23)
and the nonlinear regression is an estimation of the binding
potential with the partition coefficient constrained to be equal
in both the striatum and the cerebellum (20). In both cases, the
analysis is based upon a three-compartment model consisting
of plasma, free and nonspecifically bound tracer ([11C]WIN-
35,428) in brain, and tracer bound to the DA transporter. The
rate of binding from the plasma to the free/nonspecifically
bound compartment is denoted as K1, the reverse rate constant
is denoted by k2; the forward rate constant from the free/
nonspecifically bound compartment to the bound compart-
ment is k3 and thus represents the binding to the transporter;
and the tracer dissociation is denoted by k4. In the linear
approach, the k3/k4 ratio is estimated as a parameter. The
k3/k4 ratio is a PET scan quantitative measurement of the ratio
of transporter receptor density to the transporter affinity-i.e.,
the binding potential Bma,x/(KD-Vd). The nonlinear approach
involves a separate estimation of K1 and k2 in the cerebellum
and then in the caudate and putamen, thus four separate rate
constants are obtained; the ratio of Kl/k2 is constrained to be
equal to that derived in the cerebellum.
The volumes of the basal ganglia were measured from the Ti
weighted SPGR MRI scans, which used contiguous slices from
just superior to the lateral ventricles through the aqueduct of
Sylvius, in an oblique axial projection parallel to the AC-PC
line. The lateral ventricles (excluding the temporal horns), the
head and body of the caudate nucleus, the putamen, and the
globus pallidi were manually outlined by a trained operator.
Three-dimensional volumetric images were reconstructed with
standard clinical software (ISG, Mississauga, Ontario).
Blinded repeat measurements of these structures demonstrate
<10% reader variability.
Two-tailed unpaired Student's t tests and nonparametric
comparisons were employed. The level of significance chosen
was P < 0.05, after the appropriate correction for multiple
comparisons.
RESULTS
PET Studies with ["1C] WIN-35,428 in LND, Rett Syn-
drome, and Normal Controls. In LND, a significant reduction
was observed with [11C]WIN-35,428 binding in the caudate
(56%) and in the putamen (73%) when compared to both
normal control subjects and Rett syndrome patients (Tables 1
and 2). All three methods of estimating DA transporter
binding (listed in the tables) showed dramatic reduction in
LND compared to healthy control subjects and Rett syndrome
patients. The quantification of the binding for each method is
summarized in Tables 1 and 2.
The reduced accumulation of WIN-35,428 binding in two
patients with LND contrasted with healthy control subjects is
illustrated in Fig. 1. The results for all 6 LND subjects, 3 Rett
syndrome patients, and 10 control subjects are presented
graphically in Fig. 2 for the k3/k4 constrained method only.
Because all patients with LND are male, a specific compar-
ison with male controls was carried out and showed significant
differences in the measurements of the caudate (P < 0.03) and
the putamen (P < 0.008). When LND patients were contrasted
to Rett syndrome patients, the results were also striking for the
caudate and putamen (P < 0.003). Nonetheless, when Rett
syndrome patients were compared to normal controls, there
were no statistical differences in [11C]WIN-35,428 binding to
the DA transporter in either the caudate or the putamen.
MRI Studies/Partial Volume Correction. In this study five
patients with LND underwent volumetric measurements using




Group n Ratio (Kd.Vd) (Kd'Vd)
Normal 10 3.24 ± 0.22 6.81 ± 0.57 4.53 ± 0.38
LND 6 1.63 ± 0.33* 2.51 ± 0.30* 2.00 ± 0.25*
RS 3 4.18 ± 0.40 5.35 ± 0.26 4.57 ± 0.31
Values in the table are presented as mean ± SEM for each method
of analysis. Values are not partial volume corrected. For the ratio
method, the level of reduction was 49.7% and 61% compared to
normal and Rett syndrome (RS) patients, respectively. For the non-
linear analysis, the level of WIN-35,428 binding was reduced by 63%
and 53% compared to normal and Rett syndrome patients, respec-
tively. Using linear calculations, the values were reduced by 56%
compared to both normal and Rett syndrome patients.
*P < 0.05 when compared to normal or Rett syndrome patients.
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Group n Ratio (Kd'Vd) (Kd'Vd)
Normal 10 3.39 ± 0.29 6.57 ± 0.43 5.42 ± 0.52
1.35 ±
LND 6 1.23 ± 0.22* 1.63 ± 0.16* 0.09*
RS 3 4.37 ± 0.36 4.95 ± 0.72 4.29 ± 0.5
Values in table are presented as mean ± SEM for each analysis. For
the ratio method, binding in LND was reduced by 64% and 72% when
compared to normal and Rett syndrome (RS) patients, respectively.
For the nonlinear calculation, binding in LNDwas reduced by 75% and
67% when compared to normal and Rett syndrome patients, respec-
tively. For the linear calculation, binding inLND was reduced by 75% and
68% compared to normal and Rett syndrome patients, respectively.
*P < 0.05 when compared to Rett syndrome and normal patients.
MRI. MRI was contraindicated in a 6th patient due to the
placement of a metal implant. None of the five LND patients
showed a significant reduction in putamen volume (LND =
4006 ± 978 mm3 (1 SD); normal = 4171 ± 460 mm3, P < 0.69).
However, a significant decrease of 30% in caudate volume
(LND = 2644 ± 571 mm3; normal = 3753 ± 561 mm3, P <
0.005) was documented and compared to normal controls. To
ensure that the possible reduction in caudate volume would not
confound the results of the PET analysis, data from LND
subjects were examined by using a rigorous partial volume
correction of the time activity curves of the caudate and
putamen (24-26). In the caudate, the structure most involved
in the volumetric MRI findings, partial volume correction
resulted in a greater decrease of the caudate-cerebellum ratio
in patients compared to normal control subjects (27). The
FIG. 1. [11C]WIN-35,428 PET images in two LND and control
subjects, ages 22 (Left) and 35 (Right) years. They were acquired and
summed between 70 and 90 min postinjection and pass through the
caudate and putamen in a transverse plane parallel to the canthal-
meatal line. They were individually corrected for injected radioactiv-
ity, and then the image containing the caudate and putamen was
divided by the cerebellum on a pixel-by-pixel basis. The images were
scaled to the global highest and lowest values for all of the images of
all subjects, and hence were scaled to a common maximum and
minimum. The control subjects are matched for age. These images
demonstrate dramatic reduction in DA transporter binding in the basal
ganglia, which is consistent with a reduction in the number of DA
terminals.
results of one example are shown in Fig. 3. The partial volume
corrected measurements show that the reduction in the pre-
synaptic transporter binding in LND is not due to differences
in caudate volume.
DISCUSSION
The DA transporter is an important element of the DA-
containing neuron and is uniquely localized to dopaminergic
nerve terminals in the brain. The DA transporter has been
characterized, cloned, and subjected to structure-function
studies (28-31). As noted in the introductory comments,
destruction of dopaminergic neurons with neurotoxins results
in a major reduction of markers such as WIN-35,428 in brain
regions with dopaminergic innervation.
To our knowledge, the finding of low DA transporter
binding with WIN-35,428 in LND provides the first in vivo
documentation of a dopaminergic reduction in this disease.
The reduction in DA could be due to a loss ofDA neurons or
DA nerve terminals. However, the works of Lloyd et al. (3) in
humans and Jinnah et al. (6) in mutant mice are consistent with
DA terminal loss; direct examination of the substantia nigra
would be necessary to determine if there is definite neuronal
loss. Our findings of a DA reduction is consistent with (i) the










































FIG. 2. Scattergrams depicting [11C]WIN-35,428 binding for LND,
normal control subjects, and Rett syndrome patients in the caudate (a)
and putamen (b) by using the k3/k4 constrained method. These
scattergrams clearly show the absence ofoverlap of theLND cases with
Rett syndrome or normal control subjects. Bars show mean ± SEM.
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zymes in the caudate (65%) and putamen (90%) in postmor-
tem brain tissue of three subjects (3), (ii) the reduced levels of
DA metabolites found in the spinal fluid of LND patients (33,
34), and (iii) the reduction in DA and its synthesizing enzymes
in an HPRT-deficient mouse mutant (6). Consequently, the
loss of DA accompanying a loss of HPRT activity is now
established with the addition of the present in vivo data in
living LND patients. Furthermore, behavioral findings from
rats with self-injurious behavior whose dopaminergic neurons
were lesioned with 6-hydroxydopamine at 3 days of age
suggests that reduced DA contributes to this unique behavior
in LND (4). Although different in character from Parkinson
disease, our findings are consistent with the movement disor-
der present in LND (e.g., dystonia and choreiform move-
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FIG. 3. Effects of partial volume correction (on caudate quantifi-
cation) in a patient with LND. Time activity curves comparing a single
LND patient to a normal control for uncorrected WIN 35,428 binding
(a) and with partial volume correction (b). Partial volume correction
in this example increases the normal and patient DA transporter
binding (using the method of constrained k3/k4) from 3.86 to 10.4 and
from 1.55 to 2.50, respectively. In this single example, the original
quantification demonstrated a 60% reduction in the LND patient, but
partial volume correction revealed a reduction of 76%. We conclude
that reduciitionns in the- caudate strurircturend not in fac-t tconfonildr the-
finding, and that there is a dramatic reduction in DA transporter
binding in the caudate and putamen of LND patients compared to
controls and Rett syndrome patients.
state that disturbances of components of corticostriate circuits
underlie hypokinetic and hyperkinetic disorders (35-37). Ad-
ditional research is needed to identify the precise functional
neuropathology of LND in the DA-containing brain regions.
The LND PET studies were carried out with anesthetic
agents, thus raising the issue of whether or not anesthetics
affect binding to the DA transporter. However, no reduction
of transporter density was found in animal studies that used the
same anesthetic agents (data not shown) (19). Also, the Rett
syndrome PET studies used the same anesthesia protocol. The
lack of a significant DA transporter reduction in Rett syn-
drome suggests that anesthesia, in itself, does not result in the
reduced WIN-35,428 binding observed in LND.
In experiments that depend on binding as an index of
neuronal density, one potential difficulty that could lead to an
erroneous interpretation of the findings is the up- or down-
regulation of transporter sites occurring in response to the
changing synaptic levels of DA (32, 38). From the PET
measurement alone, it is not possible to determine whether the
decreased WIN-35,428 binding in vivo is due to a down-
regulation of the DA transporter. Both down-regulation and
loss of DA-containing neurons reduce the number of DA
transporter sites. However, findings from the HPRT-deficient
mice (6) and from LND patients support the conclusion that
a significant loss of dopaminergic nerve terminals and/or
neurons occurs (3). Furthermore, a reduction of the DA
transporter in the presence of normal DA content would
probably result in normal or elevated DA metabolites in
cerebral spinal fluid and not in the reduced level of DA
metabolites found in LND (33, 34).
Another limitation in DA transporter analysis that must be
considered is the difference in volumes of the caudate and the
putamen in patients compared to controls. Although we did
find some evidence of reduced caudate volume in the LND
cases, partial volume corrections of the volumes resulted in an
even greater reduction of the DA transporter in LND (Fig. 3)
In Rett syndrome, using MRI, Reiss et al. (39) have docu-
mented a 30% reduction in caudate volume. Since patients
with LND had similar reductions, Rett syndrome patients serve
as a control group to compare caudate size with the LND group.
The present findings might be refined by estimating absolute
transporter densities (Bmax) instead of using the ratio of density
to affinity. Other methods, using receptor blocking agents such
as mazindol to partially occupy DA transporter sites, have been
proposed as a means for absolute quantification (20) (D.F.W.,
unpublished observations). However, the methods of kinetic
analysis employed in this study currently provide the best
available estimates of DA transporter density and affinity.
Regardless of any uncertainties about the absolute degree, the
evidence for the reduction ofDA transporters in LND patients
remains striking and demonstrates that current in vivo methods
for measuring the binding potential of the DA transporter quite
adequately detect an in vivo decrease in DA content in LND.
Confirmation by our in vivo PET studies of a dopaminergic
abnormality in LND lends support to the hypothesis that the
neonatal reduction of DA in LND leads to different motor
symptoms in this disorder than those observed in Parkinson
disease. Our results are consistent with a developmental insult
affecting arborization of dopamine fibers that innervate the
striatum, in contrast to the degeneration that occurs in Par-
kinson disease (4, 5). Developmental abnormalities in striatal
organization may account for the motor symptoms in LND.
DA reduction may also be linked to self-injury. The self-injury
associated with LND worsens when LND patients are given
L-dopa (34). In addition to these clinical observations, the
hypothesis concerning a neonatal reduction of DA has re-
ceived particular support from animal studies that compared
the consequences of reducing DA neonatally in rats and
assessing for self-injury when the rats became adults. As seen
in LND patients, rats lesioned as neonates and given L-dopa
Proc. Natl. Acad. Sci. USA 93 (1996)
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showed an increased incidence of self-injury, whereas rats
lesioned as adults showed no self-injury. Therefore, the iden-
tification of a drug treatment that could block the self-injury
caused by an L-dopa challenge in the neonatal-6-hydroxy-
dopamine model is actively underway. Additionally, the de-
velopment of a therapy to prevent this DA deficiency in LND
during the developmental period is also a goal of future
investigations. The availability of the HPRT-deficient mouse
with a DA reduction in the brain will provide a model to carry
out these latter studies (6).
In summary, the findings demonstrate that the DA trans-
porter can be imaged in vivo in developmental disorders with
PET imaging. The data collected in LND clearly illustrates the
value of PET imaging in a neurodevelopmental disorder. It
documents the reduction in binding of a ligand to the DA
transporter and definitively indicates that DA content is
reduced in the neurodevelopmental disorder, LND.
We appreciate Dr. Lowell Anderson's help in the recruitment of
LND patients and the assistance of Wayne Fisher, Ph.D., and his staff
at the Kennedy-Krieger Institute in Behavior Management. Special
thanks to Dr. William Nyhan for patient referral and his advice on
patient management and Hyder Jinnah, M.D., Ph.D., for his helpful
comments. We also thank B. Chan, C. Chen, A. Kalaff, D. Clough, J.
Foss, R. Smoot, Cindy Quinn and Margaret Magnuson for technical
assistance and J. Mushachio, Ph.D., and W. Matthews, Ph.D., for
radiochemistry assistance. This work was supported in part by Grants
HD 23042, HD 24061, NS 15080, and HD 24448 from National
Institutes of Health.
1. Lesch, M. & Nyhan, W. L. (1964) Am. J. Med. 36, 561-570.
2. Seegmiller, J. E., Rosenbloom, F. M. & Kelley, W. N. (1967)
Science 155, 1682-1684.
3. Lloyd, K. G., Hornykiewicz, O., Davidson, L., Shannak, K.,
Farley, I., Goldstein, M., Shibuya, M., Kelley, W. N. & Fox, I. H.
(1981) N. Engl. J. Med. 305, 1106-1111.
4. Breese, G. R., Criswell, H. E., Duncan, G. E. & Mueller, R. A.
(1990) Brain Res. Bull. 25, 477-484.
5. Breese, G. R., Baumeister, A. A., McCown, T. J., Emerick, S. G.,
Frye, G. D., Crotty, K. & Mueller, R. A. (1984) J. Pharmacol.
Exp. Ther. 231, 343-354.
6. Jinnah, H. A., Wojcik, B. E., Hunt, M., Narang, N., Lee, K Y.,
Goldstein, M., Wamsley, J. K., Langlais, P. J. & Friedmann, T.
(1994) J. Neurosci. 14, 1164-1174.
7. Madras, B. K., Spealman, R. D., Fahey, M. A., Neumeyer, J. L.,
Saha, J. K. & Milius, R. A. (1989) Mol. Pharmacol. 36 (4),
518-524.
8. Scheffel, U., Boja, J. W. & Kuhar, M. J. (1989) Synapse 4,
390-392.
9. Hantraye, P., Brownell, A. L., Elmaleh, D., Spealman, R. D.,
Wullner, U., Brownell, G. L., Madras, B. K. & Isacson, 0. (1992)
NeuroReport 3, 265-268.
10. Kaufman, M. J. & Madras, B. K. (1992) Synapse 12, 99-111.
11. Meltzer, P. C., Liang, A. Y., Brownell, A. L., Elmaleh, D. R. &
Madras, B. K. (1993) J. Med. Chem. 36, 855-862.
12. Madras, B. K. (1994) Ann. Neurol. 35, 376-379.
13. Kuhar, M. J., Sanchez-Roa, P. M., Wong, D. F., Dannals, R. F.,
Grigoriadis, D. E., Lew, R. & Milbergen, M. (1990) Eur. Neurol.
Suppl. 30, 15-20.
14. Shaya, E. K., Scheffel, U., Dannals, R. F., Ricaurte, G. A., Car-
roll, F. I., Wagner, H. N., Jr., Kuhar, M. J. & Wong, D. F. (1992)
Synapse 10, 169-172.
15. Innis, R. B., Seibyl, J. P., Scanley, B. E., Laruelle, M., Abi-
Dargham, A., Wallace, E., Baldwin, R. M., Zea-Ponce, Y.,
Zoghbi, S., Wang, S., Gao, Y. & Neumeyer, J. L. (1993) Proc.
Natl. Acad. Sci. USA 90, 11965-11969.
16. Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D.,
Snyder, S. H., Ravert, H. T. & Dannals, R. F. (1993)Ann. Neurol.
34, 423-431.
17. Wenk, G. L., O'Leary, M., Nemeroff, C. B., Bissette, G., Moser,
H. & Naidu, S. (1993) Dev. Brain Res. 74, 67-72.
18. Lekman, A., Witt-Engerstrom, I., Gottfries, J., Hagberg, B. A.,
Percy, A. K. & Svennerholm, L. (1989) Pediatr. Neurol. 5, 357-
362.
19. Yokoi, F., Galgon, R., Yaster, M. & Wong, D. F. (1994) J. NucL.
Med. 35, 198 (abstr.).
20. Wong, D. F., Yung, B., Dannals, R. F., Shaya, E. K., Ravert,
H. T., Chen, C. A., Chan, B., Folio, T., Scheffel, U., Ricaurte,
G. A., Neumeyer, J. L., Wagner, H. N., Jr., & Kuhar, M. J. (1993)
Synapse 15, 130-142.
21. Evans, A. C., Marrett, S., Torrescorzo, J., Ku, S. & Collins, L.
(1991) J. Cereb. Blood Flow Metab. 11, A69-78 (abstr.).
22. Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L.,
Schlyer, D. J., MacGregor, R. R., Hitzemann, B., Bendriem, B. &
Gatley, J. (1990) J. Cereb. Blood Flow Metab. 10, 740-747.
23. Gjedde, A. (1982) Brain Res. Rev. 4, 237-274.
24. Rousset, 0. G., Ma, Y., Leger, G. C., Gjedde, A. H. & Evans,
A. C. (1993) in Quantification ofBrain Function: Tracer Kinetics
and Image Analysis in Brain PET, eds. Uemura, K., Lassen, N.,
Jones, T. & Kanno, I. (Elsevier, Amsterdam), pp. 113-126.
25. Rousset, O., Ma, Y., Kamber, M., Evans, A. C. (1993) Comput.
Med. Imaging Graphics 17, 373-379.
26. Rousset, 0. G., Ma, Y., Marenco, S., Wong, D. F. & Evans, A. C.
(1996) in Quantification of Brain Function: Tracer Kinetics and
Image Analysis in Brain PET, eds. Jones, T., Bailey, D., Cunning-
ham, V. & Meyers, R. (Academic, New York), in press.
27. Marenco, S., Rousset, O., Ma, Y., Yokoi, F., Chan, B., Kim, S.,
Evans, A., Kalaff, A., Sachdev, S., Bryan, R. N., Harris, J.,
Gjedde, A. & Wong, D. F. (1995) J. NucL Med. 36, 254P (abstr.).
28. Shimada, S., Kitayama, S., Lin, C. L., Patel, A., Nanthakumar, E.,
Gregor, P., Kuhar, M. & Uhl, G. (1991) Science 254, 576-578.
29. Kilty, J. E., Lorang, D. & Amara, S. G. (1991) Science 254,
578-579.
30. Giros, B., el Mestikawy, S., Bertrand, L. & Caron, M. G. (1991)
FEBS Let. 295, 149-154.
31. Usdin, T. B., Mezey, E., Chen, C., Brownstein, M. J. & Hoffman,
B. J. (1991) Proc. Natl. Acad. Sci. USA 88, 11168-11171.
32. Cerruti, C., Pilotte, N. S., Uhl, G. & Kuhar, M. J. (1994) Mol.
Brain Res. 22, 132-138.
33. Silverstein, F. S., Johnston, M. V., Hutchinson, R. J. & Edwards,
N. L. (1985) Neurology 35, 907-911.
34. Jankovic, J., Caskey, T. C., Stout, J. T. & Butler, I J. (1988) Ann.
Neurol. 23, 466-469.
35. DeLong, M. R. (1990) Trends Neurosci. 13, 281-285.
36. Alexander, G. E., DeLong, M. R. & Strick, P. L. (1986) Annu.
Rev. Neurosci. 9, 357-81.
37. DeLong, M. R., Alexander, G. E., Mitchell, S. J. & Richardson,
R. T. (1986) Progr. Brain Res. 64, 161-174.
38. Pilotte, N S., Sharpe, L. G. & Kuhar, M. J. (1994) J. Pharmacol.
Exp. Ther. 269, 963-969.
39. Reiss, A. L., Faruque, F., Naidu, S., Abrams, M., Beaty, T.,
Bryan, R. N. & Moser, H. (1993) Ann. Neurol. 34, 227-234.
Medical Sciences: Wong et aL
